Skip to content
Screener

Glaukos GKOS Net Change in Cash

Net Change in Cash at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$504.6M+53.2%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
-$5.21M+28.3%
AbbVie logo
AbbVieABBV
$4.16B+1,293%
Schering-Plough logo
Schering-PloughSGP
$142.54M+242%
Bausch + Lomb logo
Bausch + LombBLCO
-$118M-16.8%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Principal paid on finance lease(640)(526)
Net cash provided by financing activities16,7604,195
Effect of exchange rate changes on cash and cash equivalents(1,302)(4,635)
Net increase (decrease) in cash, cash equivalents and restricted cash22,953(69,712)
Cash, cash equivalents and restricted cash at beginning of period94,647174,359
Cash, cash equivalents and restricted cash at end of period$117,600$104,647
Supplemental disclosures of cash flow information
Taxes paid, net of refunds$868$511

Item 1. Financial Statements

FAQ

What is Glaukos's net change in cash?
Glaukos (GKOS) reported net change in cash of $9.52M in Q2 2026.
How has Glaukos's net change in cash changed year-over-year?
Glaukos's net change in cash increased by 166.4% year-over-year, from -$14.34M to $9.52M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Glaukos's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude